Description
Mitomycin C is an alkaloid initially produced by Streptomyces that exhibits antibiotic, immunomodulatory, and anticancer chemotherapeutic activities. Mitomycin C increases heart allograft transplant survival rates by decreasing activation of CD4+ T cells and lymph nodes and increasing the number of circulating Treg cells. Mitomycin C inhibits thioredoxin reductase and induces DNA cross-linking at CpG sequences. Clinically, mitomycin C is used as a combination therapy to treat cancers; it suppresses cell growth by preventing DNA strand break repair.
References
Liu L, Wang F, Zheng Y, et al. Pretreatment of transfused donor splenocytes and allografts with mitomycin C attenuates acute rejection in heart transplantation in mice. Transplant Proc. 2014 May;46(4):1169-74. PMID: 24815153.
Paz MM, Zhang X, Lu J, et al. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol. 2012 Jul 16;25(7):1502-11. PMID: 22694104.
Kang YH, Lee KA, Kim JH, et al. Mitomycin C modulates DNA-double strand break repair genes in cervical carcinoma cells. Amino Acids. 2010 Nov;39(5):1291-8. PMID: 20352460.
Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995 Sep;2(9):575-9. PMID: 9383461.
